Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. Report: Q3 medical device recalls hit highest point since at least 2000
Medical device recalls have reached their highest point since 2000, according to a new report from Stericycle‘s ExpertSolutions business.
Numbers for med device recalls rose 29% over the previous quarter, according to the report, up to 339. Recalled devices increased 187% to approximately 116 million, the highest number since Q3 of 2012. Read more
4. Light-driven motor powers nanorobot drug delivery system
Researchers proposed a nanosized, light-driven motor that is powerful enough to carry a certain load and possible act as a drug delivery system, according to the study published in the Journal of Chemical Physics.
“The unprecedented characteristics of dipole photomotors based on semiconductor nanoclusters offer the prospect of more than just addressing a certain scarcity of the translational photomotors family,” lead researcher Leonid Trakhtenberg of the Moscow Institute of Physics and Technology said in prepared remarks. “These devices could actually be applied wherever rapid nanoparticle transport is required. In chemistry and physics, they could help develop new analytical and synthetic instruments, while in biology and medicine they could be used to deliver drugs to diseased tissues, improve gene therapy strategies, and so on.” Read more
3. Zimmer Biomet touts preliminary data for stem cell therapy
Zimmer Biomet touted data today from an investigational device exemption trial evaluating the use of autologous concentrated bone marrow aspirate for the treatment of critical limb ischemia. The stem cell study is the 1st pivotal trial of its kind to complete enrollment and a 1-year follow-up in a patient population that is ineligible for revascularization, the company said.
Warsaw, Ind.-based Zimmer Biomet’s trial is a prospective, randomized, double-blind study of stem cells injected intramuscularly into the affected limb to prevent or delay major amputation or death in patients with critical limb ischemia. The primary efficacy endpoint is the time to major amputation and all-cause mortality at 1 year. Read more
2. Boston Scientific buys Resectr tissue resection device from Distal Access
Boston Scientific said today that it acquired the Resectr tissue resection device from Distal Access for an undisclosed amount.
The buy covers the gynecology and urology portfolio of Salt Lake City-based Distal Access, Boston Scientific said. The Resectr device is designed for polypectomies to remove uterine polyps. Read more
1. Doc wins $20m from Medtronic in spine patents spat
A doctor suing Medtronic last week won $20.3 million in damages after a federal jury in Texas found that the company infringed his patents covering spinal deformity repair devices.
Dr. Mark Barry sued Medtronic in February 2014 in the U.S. District Court for Eastern Texas, alleging infringement of a trio of patents covering a “System and method for aligning vertebrae in the amelioration of aberrant spinal column deviation conditions.” (The 3rd patent was later dropped from the suit; Barry licenses the patents to Zimmer Biomet). Read more
The post MassDevice.com +5 | The top 5 medtech stories for November 15, 2016 appeared first on MassDevice.
from MassDevice http://ift.tt/2fSdpI9
Cap comentari:
Publica un comentari a l'entrada